Cécile Vienney

Ceo/president at HYPREVENTION

Cécile Vienney is the CEO/President and founder of Hyprevention, a company that develops implantable medical devices for fracture treatment and prevention using the STRUTPLASTY Technique. Vienney also serves as the CEO/President of Hyprevention INC and previously worked as the COO at Vexim before it became a part of Stryker. With a background in mechanical engineering from Polytech Lille, Vienney also has experience as a Managing Director at C-OPM Consulting.

Location

New York, United States

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


HYPREVENTION

Founded in 2010 by Cécile Vienney (CEO) and 3 orthopedic surgeons, Hyprevention is a French start-up located in France that develops, manufactures and markets implantable medical devices to reinforce weaken bone by osteoporosis or cancer thanks to the STRUTPLASTY® Technology. In 2021, Hyprevention INC was established in New-York - USA to promote V-STRUT© Vertebral Implant FDA cleared. www.hyprevention.com www.hypreventionusa.com V-STRUT© Vertebral Implant is indicated to treat vertebral fractures. The device is made of PEEK polymer, close to normal bone, and presents a pedicle anchorage to reinforce the full vertebrae. It is a unique solution on the market aiming to rebalance antero-posterior loading and stress. With aging, bone quality decreases due to osteoporosis, increasing the risk of vertebral compression fractures). Osteoporosis is the most common disease affecting the elderly population. As a result, the vertebral body is at risk of fracture with about 750 000 vertebral compression fractures per year in the US alone among which 250 000 require treatment. Y-STRUT® Hip Implant (not available in US) is intended to prevent a contra-lateral fracture in patients at risk due to bone fragility linked to osteoporosis. Implementation of a contralateral Y-STRUT is performed during the same anesthesia as practiced for the treatment of the original fracture. The duration of hospitalization remains unchanged. Contralateral Y-STRUT requires no specific rehabilitation. Hip fracture affects more than 2 million people worldwide every year. This number will reach more than 6 million in 2050, due to an aging and increasing population. At 1 year, 9% of patients will have a contra-lateral fracture, at 5 years this rises to 20%. After a second contralateral fracture, loss of autonomy is almost certain to prevent a return home. Mortality is multiplied by 2. The prevention of hip fracture improves the quality of life of older people by allowing them to retain their autonomy.


Headquarters

Pessac, France

Employees

1-10

Links